ASCO GU 2019: Avelumab plus axitinib combination superior to sunitinib
The results from the following study were presented at the [...]
Nivolumab plus ipilimumab combination shows survival benefit for patients with untreated kidney cancer at 30 months
Further survival data has been released from the phase 3 [...]
Four distinct subgroups of clear cell renal cancer identified
Using gene profiling, a recent study published in Cancer Discovery [...]
Potential of microRNAs as biomarkers for renal cell carcinoma
A recent review of the knowledge about the potential clinical [...]
